Company Overview and News

 
Early learning property trust Folkestone a smart bet for investors

2017-09-22 scmp
Folkestone Education Trust owns more than 400 childcare centres and says it is growing at over three times the speed of its competitor

 
Six childcare centres offered in one line

2017-04-04 theage.com.au
A portfolio of six newly developed Victorian childcare centres offered to the market for the first time are expected to fetch $50 million.

 
Six childcare centres offered in one line

2017-04-04 smh.com.au
A portfolio of six newly developed Victorian childcare centres offered to the market for the first time are expected to fetch $50 million.

 
Kids boost bottom line for childcare landlords

2017-02-14 theage.com.au
Parents, do you love and value your kids? Well you're not alone, corporate Australia does too.

 
Kids boost bottom line for childcare landlords

2017-02-14 smh.com.au
Parents, do you love and value your kids? Well you're not alone, corporate Australia does too.

 
Boom time for corporate childcare in Australia

2016-11-12 smh.com.au
Parents paying up to $190 a day for childcare places which are propping up $1 billion in profits for private childcare operators and their landlords, with questions being asked about who is really benefiting from billions in taxpayer subsidies for the sector.

 
Centuria Metro on expansion path

2016-08-09 theage.com.au
Centuria​ Metropolitan office trust is on an expansion path as it looks to beat its maiden full-year result of $44.8 million and achieve the forecast 3 per cent earnings guidance for the current financial year.

 
Centuria Metro on expansion path

2016-08-09 smh.com.au
Centuria​ Metropolitan office trust is on an expansion path as it looks to beat its maiden full-year result of $44.8 million and achieve the forecast 3 per cent earnings guidance for the current financial year.

 
Melbourne Asset Tour Booklet

2016-04-27 asx.com.au

 
Appendix 3Y

2016-04-21 asx.com.au

 
Appendix 3B

2016-04-20 asx.com.au

 
 
Dividend/Distribution - FET

2016-03-23 asx.com.au

 
CHANGE OF ADDRESS

2016-03-18 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...